{"schema_version":"secwatch.filing_event.v1","accession":"0001789769-24-000020","form_type":"8-K","ticker":"TIL","cik":"0001789769","company_name":"Instil Bio, Inc.","filed_at":"2024-01-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.544609+00:00","generated_at":"2026-06-06T22:01:37.970593+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Instil Bio enters collaboration for ITIL-306 preclinical manufacturing feasibility studies","bullets":["Agreement with collaborator for preclinical manufacturing feasibility studies on ITIL-306 program.","Aims to enroll patients in investigator-initiated clinical trials (IITs).","No guidance provided on timing of data readout for ITIL-306 or IIT studies.","Forward-looking statements subject to risks including manufacturing and enrollment uncertainties."],"urls":{"canonical":"https://secwatch.observer/filing/0001789769-24-000020","json":"https://secwatch.observer/filing/0001789769-24-000020.json","markdown":"https://secwatch.observer/filing/0001789769-24-000020.md","text":"https://secwatch.observer/filing/0001789769-24-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789769/000178976924000020/0001789769-24-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789769/000178976924000020/til-20240117.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T22:01:37.970593+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}